Skip to content
Menu
Ivermectin in Africa
  • About
  • Contact
  • Forum
  • I-MASK+ Protocol
  • MATH+ Protocol
  • Zimbabwe SID Protocol
Ivermectin in Africa

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Posted on December 24, 2020
FRONTIERS SUBMISSION FINAL PREPRINTDownload

In March 2020, an expert panel called the Front Line COVID-19 Critical Care Alliance (FLCCC) was created and led by Professor Paul E. Marik, with the goal of continuously reviewing the rapidly emerging basic science, translational, and clinical data in order to gain insight into and to develop a treatment protocol for COVID-19.

At the same time, many centers and groups employed a multitude of novel therapeutic agents empirically, and within clinical trials, often during inappropriate time points during this now well-described multi-phase disease.

Either as a result of these frequent trial design failures, or due to the lack of their insufficient anti-viral or anti-inflammatory properties, nearly all trialed agents have proven ineffective in treating COVID-19 as of November 11, 2020.

Based on a recent series of negative published therapeutic study results, in particular the SOLIDARITY trial, they now virtually eliminate any treatment role for remdesivir, hydroxychloroquine, lopinavir/ritonavir, interferon, convalescent plasma, tocilizumab, and monoclonal antibody therapy.

Despite this growing list of failed therapeutics in COVID-19, the FLCCC recently discovered that ivermectin, an anti-parasitic medicine, has highly potent real-world, anti-viral, and anti-inflammatory properties against SARS-CoV-2 and COVID-19.

This conclusion is based on the increasing numbers of study results reporting effectiveness, not only within vitro and animal models, but also in numerous randomized and observational controlled clinical trials.

Repeated, large magnitude improvements in clinical outcomes have now been recorded when ivermectin is used not only as a prophylactic agent but also in mild, moderate, and even severe disease states.

The review that follows of the existing evidence for ivermectin relies on “emerging” data in that, although compelling, only a minority of studies have been published in peer-reviewed publications with the majority of results compiled from manuscripts uploaded to medicine pre-print servers or posted on clinicaltrials.gov.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About This Site

Learn more about Ivermectin use for the prophylaxis and treatment of Covid-19. Learn about its history and how it may become a key therapy to fight the current Covid-19 pandemic.

This blog is maintained by Dr Martin Gill, an ENT specialist based in Johannesburg, South Africa.

Categories

  • Africa
  • Experimental
  • In the Media
  • Resources
  • Uncategorized
  • Webinar
  • World

South Africa Covid-19 Update

Recent Comments

  • G on Zimbabwe SID Protocol
  • Ben on Zimbabwe SID Protocol
  • Gillian on Zimbabwe SID Protocol
  • Dr. Glynn Goedhart on Zimbabwe SID Protocol
  • Donna Scholtz on Zimbabwe SID Protocol
©2023 Ivermectin in Africa | WordPress Theme: EcoCoded